Tag: equity
-
GSK, 23andMe Ink Precision Meds Discovery Deal
Consumer genetics company 23andMe signed a 4-year agreement to help drug maker GlaxoSmithKline find more precise drug targets and recruit clinical trial participants likely to respond to treatments.
-
A.I. Drug Discovery Company Gains $32M in Early Funds
A company using genomic databases and artificial intelligence to discover new therapies for neurodegenerative diseases is raising $32 million in its first venture funding round.
-
New $315 Million Life Sciences Venture Fund Unveiled
A life science and health care investment company in the U.K. today revealed its 12th venture capital fund for start-up and current enterprises in the U.S. and Europe.
-
Infographic – Amazon’s Largest Acquisitions
Our friends at CB Insights put together a chart showing Amazon’s largest acquisitions in dollar value, this weekend’s infographic.
-
Cancer T-Cell Start-Up Gains $150 Million in IPO
A three year-old company developing treatments for cancer with engineered T-cells from the immune system raised $150 million in its initial public offering of common stock.
-
$3.4M NIH Grant Funding New ALS Treatments
A biotechnology company is receiving a grant from National Institute of Neurological Disorders and Stroke to advance its experimental treatments for amyotrophic lateral sclerosis, or ALS.
-
Bacterial Genome Recoded to Produce Stable Protein Drugs
A biotechnology lab devised techniques for genetically engineered bacteria to produce synthetic proteins that can last longer and are more stable than current protein production methods.
-
Patent Awarded for Nasal Delivered Cancer Immunotherapy
A technology for cancer therapies that harnesses the immune system with nanoscale droplets suspended in an emulsion and delivered through the nose received a U.S. patent.
-
FDA Okays A.I.-Guided Wrist Fracture Software
The U.S. Food and Drug Administration authorized marketing of software to help diagnose wrist fractures using machine-learning algorithms to read and interpret X-ray images.
-
Infographic – Graphene Investment in Decline
In a report this week, our friends at CB Insights note that the investment community is waiting for graphene to reach a critical commercial mass, but their patience may be running out.